This study demonstrated that the BH scaffold, an autologous biodegradable matrix, enabled delivery of ultra-low rhBMP-2 doses that achieved rapid and consistent bone regeneration, and outperformed the clinically used ACS. This has significant clinical implications, as the BH scaffold offers a promising biomaterial-free solution for precise rhBMP-2 delivery, enhancing rapid bone regeneration while minimizing dosage, reducing adverse effects, and lowering treatment costs, making it an effective intervention for complex bone injuries.
Glatt et al. (Mon,) studied this question.